GC-Rise Pharmaceutical To Launch Remifemin In China
This article was originally published in PharmAsia News
Executive Summary
GC-Rise Pharmaceutical, a firm focusing on women's health, will launch Remifemin in the country soon. The drug, made from the extract of the medicinal plant black cohosh for treating menopausal symptoms, is produced by German company Schaper & Brümmer. Remifemin has been used worldwide for more than 50 years; its effectiveness and reliability have also been proven by strict trials in several Chinese authoritative clinical centers. Patients who are not candidates for hormone replacement therapy or who have concerns about the therapy's safety will have more choice after Remifemin enters the market. (Click here for more - Chinese Language)
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.